| ||||||||||||||
|
|
|||||||||||||
Anesthesia & Analgesia, Vol 83, 223-227, Copyright © 1996 by International Anesthesia Research Society
GENERAL ARTICLES |
M Kikura, MK Lee and JH Levy
Department of Anesthesiology, Emory University School of Medicine, Emory Clinic, Atlanta, Georgia 30322, USA.
There are no clinically available alternatives for reversing heparin in protamine-allergic patients. This study examined the ability of methylene blue, hexadimethrine, and vancomycin to reverse circulating heparin so that these compounds can be carefully examined in future placebo-controlled studies in humans. Heparin activity in blood obtained from extracorporeal circuits was reversed by adding protamine (13.5, 27.0, 81.1, 135.1, and 270.3 micrograms/mL), methylene blue (13.5, 27.0, 135.1, 202.7, 270.3, 337.8, 405.4, 473.0, 540.5, and 810.8 micrograms/mL), hexadimethrine (6.8, 13.5, 20.3, 27.0, 81.1, and 135.1 micrograms/mL), or vancomycin (13.5, 27.0, 135.1, 270.3, 540.5, and 810.8 micrograms/mL), and activated clotting times (ACTs) were measured with kaolin (n = 18). Heparinase-ACT was obtained to determine complete reversal. Heparin concentrations were 3.3 +/- 0.3 U/mL with ACT values of 485 +/- 97 s. The ACT at a protamine concentration of 81.1 micrograms/mL and at hexadimethrine concentrations of 81.1 and 135.1 micrograms/mL was not statistically different from heparinase-ACT; however, methylene blue or vancomycin did not reverse the anticoagulation at any concentrations. Hexadimethrine can reverse heparin-induced anticoagulation after cardiopulmonary bypass as well as protamine, although methylene blue or vancomycin did not neutralize heparin in vitro.
This article has been cited by other articles:
![]() |
J. Hirsh, K. A. Bauer, M. B. Donati, M. Gould, M. M. Samama, and J. I. Weitz Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 141S - 159S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hirsh and R. Raschke Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 188S - 203S. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Grayling and C. D. Deakin Methylene blue during cardiopulmonary bypass to treat refractory hypotension in septic endocarditis J. Thorac. Cardiovasc. Surg., February 1, 2003; 125(2): 426 - 427. [Full Text] [PDF] |
||||
![]() |
J. Hirsh, T. E. Warkentin, S. G. Shaughnessy, S. S. Anand, J. L. Halperin, R. Raschke, C. Granger, E. M. Ohman, and J. E. Dalen Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest, January 1, 2001; 119(1_suppl): 64S - 94S. [Full Text] [PDF] |
||||
![]() |
M. P. Merker, R. D. Bongard, N. J. Kettenhofen, Y. Okamoto, and C. A. Dawson Intracellular redox status affects transplasma membrane electron transport in pulmonary arterial endothelial cells Am J Physiol Lung Cell Mol Physiol, January 1, 2002; 282(1): L36 - L43. [Abstract] [Full Text] [PDF] |
||||
|